gebhart/patrepeval huggingface dataset:
Pharmaceutical Dosage Forms: Disperse Systems (1988)

Pharmaceutical Suspensions, Robert A. Nash Pharmaceutical Emulsions and Microemulsions, Lawrence H. Block Antacids and Clay Products, Richard J. Harwood, Joseph R. Luber, and Edward W. Sunbery Oral Aqueous Suspensions, Clyde M. Ofner, III, Roger L. Schnaare, and Joseph B. Schwartz Topical Suspensions, Hridaya N. Bhargava, Daniel W. Nicolai, and Bharat J. Oza Reconstitutable Suspensions, Clyde M. Ofner, III, Roger L. Schnaare, and Joseph B. Schwartz Injectable Emulsions and Suspensions, Alison Green Floyd and Sunil Jain Aerosol Suspensions and Emulsions, John J. Sciarra Ophthalmic Ointments and Suspensions, Khrishna M. Bapatla and Gerald Hecht Gels, Joel L. Zatz and Gregory P. Kushla Toothpastes, David Garlen Suppository Development and Production, Marion Gold, Murti VePuri, and Lawrence H. Block
How TRAIL Kills Cancer Cells, But Not Normal Cells (1997)

CANCER RESEARCHCancer cells are much more susceptible than normal cells to the cell-death-inducing effects of a protein known as TRAIL, a difference that may aid researchers who want to develop new cancer therapies. The reason for the difference has been unclear, but three groups, two of them writing on pages [815][1] and [818][2] of this issue, have now solved the puzzle: Normal cells, but apparently not cancer cells, produce a decoy receptor that binds TRAIL, but is incapable of transmitting its death message to the cell interior.

 [1]: http://www.sciencemag.org/cgi/content/short/277/5327/815
 [2]: http://www.sciencemag.org/cgi/content/short/277/5327/818
Effect of intranasal dexmedetomidine or intranasal midazolam on prevention of emergence agitation in pediatric strabismus surgery: A randomized controlled study (2016)

Background: Following strabismus surgery under sevoflurane anesthesia children often experience emergence agitation (EA) and postoperative vomiting (POV). This study compared the effects of premedication with intranasal dexmedetomidine, midazolam, and placebo on postoperative EA and POV. Methods: 105 children (aged 1–7 years) undergoing elective strabismus surgery under sevoflurane anesthesia were randomly assigned to one of three groups (n = 35 each). Preoperatively, group D received intranasal (IN) dexmedetomidine (1 μg/kg), group M received IN midazolam (0.1 mg/kg), and group C received (1 ml) IN normal saline. Agitation scores (Pediatric Anesthesia Emergence Delirium [PAED] scale) and POV were assessed in post-anesthesia care unit (PACU). The incidence of intraoperative Oculocardiac Reflex OCR events, Time to spontaneous eye opening, Postoperative pain score, total consumption of rescue analgesia and time to discharge from PACU were also assessed. Results: 98 children completed the study. Incidence of agitation (defined as PAED score ⩾ 10) was significantly higher in the control group and the midazolam group than in the dexmedetomidine group (P = 0.014), and the number of patients who developed severe agitation requiring fentanyl (PAED score ⩾ 15) was also higher in the control group (P = 0.042). There was no significant difference between the incidence of POV in the PACU between the control group (28%) and the midazolam group (21%); however, the incidence was significantly lower in the dexmedetomidine group (15%). The number of intraoperative OCR events was significantly higher in the control group (39%) than in the dexmedetomidine (0%; P = 0.006) and in the midazolam group the incidence was higher than the dexmedetomidine (9%; 3 events) but did not reach statistical significance. Conclusion: Administration of intranasal dexmedetomidine to children undergoing strabismus surgery under sevoflurane anesthesia resulted in a reduced incidence of EA compared with intranasal midazolam or placebo. The incidence of POV and intraoperative OCR was also significantly lower with dexmedetomidine.
Review: Recombinant human erythropoietin: novel strategies for neuroprotective/neuroregenerative treatment of multiple sclerosis (2008)

Treatment of multiple sclerosis (MS) is still unsatisfactory and essentially non-existing for the progressive course of the disease. Recombinant human erythropoietin (EPO) may be a promising neuroprotective/neuroregenerative treatment of MS. In the nervous system, EPO acts anti-apoptotic, antioxidative, anti-inflammatory, neurotrophic and plasticity-modulating. Beneficial effects have been shown in animal models of various neurological and psychiatric diseases, including different models of experimental autoimmune encephalomyelitis. EPO is also effective in human brain disease, as shown in double-blind placebo-controlled clinical studies on ischemic stroke and chronic schizophrenia. An exploratory study on chronic progressive MS yielded lasting improvement in motor and cognitive performance upon high-dose long-term EPO treatment.
Selectively Targeting Prostate Cancer with Antiandrogen Equipped Histone Deacetylase Inhibitors (2013)

Diverse cellular processes relevant to cancer progression are regulated by the acetylation status of proteins. Among such processes is chromatin remodeling via histone proteins, controlled by opposing histone deacetylase (HDAC) and histone acetyltransferase (HAT) enzymes. Histone deacetylase inhibitors (HDACi) show great promise in preclinical cancer models, but clinical trials treating solid tumors have failed to improve patient survival. This is due in part to an inability of HDACi to effectively accumulate in cancerous cells. To address this problem we designed HDACi with secondary pharmacophores to facilitate selective accumulation in malignant cells. We present the first example of HDACi compounds targeted to prostate tumors by equipping them with the additional ability to bind the androgen receptor (AR) with nonsteroidal antiandrogen moieties. Leads among these new dual-acting molecules bind to the AR and halt AR transcriptional activity at lower concentrations than clinical antiandrogens. They inhibit key isoforms of HDAC with low nanomolar potency. Fluorescent microscopy reveals varying degrees of AR nuclear localization in response to these compounds that correlates with their HDAC activity. These biological properties translate into potent anticancer activity against hormone-dependent (AR+) LNCaP and to a lesser extent against hormone-independent (AR-) DU145 prostate cancer, while having greatly reduced toxicity in noncancerous cells. This illustrates that engaging multiple biological targets with a single chemical probe can achieve both potent and cell-type-selective responses.
Simultaneous imaging of tissue motion and flow velocity using 2D phase-coupled speckle tracking (2010)

We introduce a new method for simultaneous imag ing of tissue motion and flow with subsample accuracy in both axial and lateral directions. The method utilizes a phase-coupled 2D speckle tracking approach, which employs the true 2D complex cross correlation to find subpixel displacements in both axial and lateral directions. We have also modified the imaging sequence on a Sonix RP scanner to allow high frame rate 2D data collection in a limited field of view covering the region of interest (M2D-mode). Together with the robust 2D speckle tracking method, M2D imaging allows for capturing the full dynamics of the flow and wall/tissue motion, even when the flow is primarily in the lateral direction (with respect to the imaging beam). The fine vector displacement estimates in both axial and lateral directions are shown to allow for smooth and contiguous strain and shear strain calculations with minimal filtering. The quality of the displacement and strain fields is demonstrated by experimental results from a flow phantom (ATS Model 524) and in vivo images of the carotid artery in a healthy volunteer. The results clearly demonstrate the feasibility of simultaneous imaging of the vector flow field and the wall/tissue motion and the corresponding strains at high spatial and temporal sampling. This may provide an essential tool in modeling the fluid-solid interactions between the blood and blood vessel, a key challenge in vascular biomechanics.
Progress towards ignition on the National Ignition Facility (2013)

The National Ignition Facility (NIF) at Lawrence Livermore National Laboratory includes a precision laser system now capable of delivering 1.8 MJ at 500 TW of 0.35-μm light to a target. NIF has been operational since March 2009. A variety of experiments have been completed in support of NIF's mission areas: national security, fundamental science, and inertial fusion energy. NIF capabilities and infrastructure are in place to support its missions with nearly 60 X-ray, optical, and nuclear diagnostic systems. A primary goal of the National Ignition Campaign (NIC) on the NIF was to implode a low-Z capsule filled with ∼0.2 mg of deuterium-tritium (DT) fuel via laser indirect-drive inertial confinement fusion and demonstrate fusion ignition and propagating thermonuclear burn with a net energy gain of ∼5–10 (fusion yield/input laser energy). This requires assembling the DT fuel into a dense shell of ∼1000 g/cm3 with an areal density (ρR) of ∼1.5 g/cm2, surrounding a lower density hot spot with a temperature of ∼10 keV and a ρR ∼0.3 g/cm2, or approximately an α-particle range. Achieving these conditions demand precise control of laser and target parameters to allow a low adiabat, high convergence implosion with low ablator fuel mix. We have demonstrated implosion and compressed fuel conditions at ∼80–90% for most point design values independently, but not at the same time. The nuclear yield is a factor of ∼3–10× below the simulated values and a similar factor below the alpha dominated regime. This paper will discuss the experimental trends, the possible causes of the degraded performance (the off-set from the simulations), and the plan to understand and resolve the underlying physics issues.
A novel function of Aft1 in regulating ferrioxamine B uptake: Aft1 modulates Arn3 ubiquitination in Saccharomyces cerevisiae (2009)

Aft1 is a transcriptional activator in Saccharomyces cerevisiae that responds to iron availability and regulates the expression of genes in the iron regulon, such as FET3, FTR1 and the ARN family. Using a two-hybrid screen, we found that Aft1 physically interacts with the FOB (ferrioxamine B) transporter Arn3. This interaction modulates the ability of Arn3 to take up FOB. The interaction between Arn3 and Aft1 was confirmed by beta-galactosidase, co-immunoprecipitation and SPR (surface plasmon resonance) assays. Truncated Aft1 had a stronger interaction with Arn3 and caused a higher FOB-uptake activity than full-length Aft1. Interestingly, only full-length Aft1 induced the correct localization of Arn3 in response to FOB. Furthermore, we found Aft1 affected Arn3 ubiquitination. These results suggest that Aft1 interacts with Arn3 and may regulate the ubiquitination of Arn3 in the cytosolic compartment.
Synthesis of 4′-C-Methylnucleosides (1993)

Several 4'-C-methylnucleosides were prepared. 1H-NMR studies on these nucleotides showed that they have the 3'-exo furanose ring conformation different from the 3'-endo conformation of natural nucleosides.
Cerebral Arterial Spasm – A Controlled Trial of Nimodipine in Patients with Subarachnoid Hemorrhage (1983)

We enrolled 125 neurologically normal patients with intracranial aneurysms in a multi-institution, prospective, double-blind, randomized, placebo-controlled trial within 96 hours of their subarachnoid hemorrhage, to determine whether treatment with the calcium blocker nimodipine would prevent or reduce the severity of ischemic neurologic deficits from arterial spasm. A deficit from cerebral arterial spasm that persisted and was severe or caused death by the end of the 21-day treatment period occurred in 8 of 60 patients given placebo and in 1 of 56 given nimodipine (P = 0.03, Fisher's exact test). Analysis of the amount of basal subarachnoid blood on pre-entry CAT scans in patients with deficits from spasm showed that an increase in subarachnoid blood was not associated with a worse neurologic outcome among patients who received nimodipine, unlike the situation in patients given a placebo. There were no side effects from nimodipine. We conclude that nimodipine should be given to patients who are neurologically normal after subarachnoid hemorrhage in order to reduce the occurrence of severe neurologic deficits due to cerebral arterial spasm.
Folates and antifolates in rheumatoid arthritis (2013)

Abstract Almost all current standard treatment of care for patients with chronic inflammatory diseases such as rheumatoid arthritis (RA) includes the folate antagonist methotrexate (MTX). Despite the proven efficacy of MTX in RA treatment, it is anticipated that further improvement of antifolate-based therapies can be achieved by integrating the continuously extending knowledge of parameters underlying drug efficacy. Herein, an overview will be presented of strategies that may assist in the future design of rationalized and personalized targeted therapies with a folate antagonist. Issues that will be discussed include (i) early detection of arthritis, (ii) genomic studies of folate/MTX pathway genes for MTX response predictions, (iii) identification of MTX resistance modalities, (iv) exploration of second/third generation of antifolates which may substitute for MTX, and (v) folate (food) supplementation.
Activation of CaMKIV by soluble amyloid-β 1–42 impedes trafficking of axonal vesicles and impairs activity-dependent synaptogenesis (2017)

The prefibrillar form of soluble amyloid-β (sAβ<sub>1-42</sub>) impairs synaptic function and is associated with the early phase of Alzheimer's disease (AD). We investigated how sAβ<sub>1-42</sub> led to presynaptic defects using a quantum dot-based, single particle-tracking method to monitor synaptic vesicle (SV) trafficking along axons. We found that sAβ<sub>1-42</sub> prevented new synapse formation induced by chemical long-term potentiation (cLTP). In cultured rat hippocampal neurons, nanomolar amounts of sAβ<sub>1-42</sub> impaired Ca<sup>2+</sup> clearance from presynaptic terminals and increased the basal Ca<sup>2+</sup> concentration. This caused an increase in the phosphorylation of Ca<sup>2+</sup>/calmodulin-dependent protein kinase IV (CaMKIV) and its substrate synapsin, which markedly inhibited SV trafficking along axons between synapses. Neurons derived from a transgenic AD mouse model had similar defects, which were prevented by an inhibitor of CaMK kinase (CaMKK; which activates CaMKIV), by antibodies against Aβ<sub>1-42</sub>, or by expression a phosphodeficient synapsin mutant. The CaMKK inhibitor also abolished the defects in activity-dependent synaptogenesis caused by sAβ<sub>1-42</sub> Our results suggest that by disrupting SV reallocation between synapses, sAβ<sub>1-42</sub> prevents neurons from forming new synapses or adjusting strength and activity among neighboring synapses. Targeting this mechanism might prevent synaptic dysfunction in AD patients.
Pseudomonas aeruginosa AlgB, which modulates the expression of alginate, is a member of the NtrC subclass of prokaryotic regulators (1992)

The Pseudomonas aeruginosa exopolysaccharide alginate is an important virulence factor in chronic pulmonary infections of cystic fibrosis patients. We determined the nucleotide sequence of the gene, algB, which regulates the level of exopolysaccharide produced by mucoid P. aeruginosa. The predicted amino acid sequence of AlgB revealed a high degree of similarity to the regulatory proteins in the NtrC subclass of 'two-component regulatory systems'. AlgB expression in Escherichia coli minicells showed a molecular weight of approximately 50,000 Da, comparable to that of the inferred amino acid sequence (49,318 Da). We show that algB is transcriptionally active in mucoid strains of P. aeruginosa and regulates the expression of the alginate biosynthetic gene, algD, thereby resulting in increased expression of alginate in mucoid P. aeruginosa.
The 14–Amino Acid CLV3, CLE19, and CLE40 Peptides Trigger Consumption of the Root Meristem in Arabidopsis through a CLAVATA2 -Dependent Pathway (2005)

CLAVATA3 (CLV3), CLV3/ESR19 (CLE19), and CLE40 belong to a family of 26 genes in Arabidopsis thaliana that encode putative peptide ligands with unknown identity. It has been shown previously that ectopic expression of any of these three genes leads to a consumption of the root meristem. Here, we show that in vitro application of synthetic 14-amino acid peptides, CLV3p, CLE19p, and CLE40p, corresponding to the conserved CLE motif, mimics the overexpression phenotype. The same result was observed when CLE19 protein was applied externally. Interestingly, clv2 failed to respond to the peptide treatment, suggesting that CLV2 is involved in the CLE peptide signaling. Crossing of the CLE19 overexpression line with clv mutants confirms the involvement of CLV2. Analyses using tissue-specific marker lines revealed that the peptide treatments led to a premature differentiation of the ground tissue daughter cells and misspecification of cell identity in the pericycle and endodermis layers. We propose that these 14-amino acid peptides represent the major active domain of the corresponding CLE proteins, which interact with or saturate an unknown cell identity-maintaining CLV2 receptor complex in roots, leading to consumption of the root meristem.
Isolation of cDNA clones encoding the human Sm B/B′auto‐immune antigen and specifically reacting with human anti‐Sm auto‐immune sera (1989)

A cDNA clone for the human SmB and B' auto-immune antigens has been isolated by antibody screening of a cDNA expression library. The cDNA clone hybridises with two distinct mRNAs, one of which is expressed in a tissue-specific manner. A fusion protein expressed from the cDNA clone was recognised by a number of sera from systemic lupus erythematosus (SLE) patients containing anti-Sm antibodies but not by sera reactive with other auto-immune antigens. The potential use of this clone in a diagnostic assay for SLE and in elucidating the processes regulating the expression of SmB and B' is discussed.
Optimal training design for MIMO OFDM systems in mobile wireless channels (2003)

This paper describes a least squares (LS) channel estimation scheme for multiple-input multiple-output (MIMO) orthogonal frequency division multiplexing (OFDM) systems based on pilot tones. We first compute the mean square error (MSE) of the LS channel estimate. We then derive optimal pilot sequences and optimal placement of the pilot tones with respect to this MSE. It is shown that the optimal pilot sequences are equipowered, equispaced, and phase shift orthogonal. To reduce the training overhead, an LS channel estimation scheme over multiple OFDM symbols is also discussed. Moreover, to enhance channel estimation, a recursive LS (RLS) algorithm is proposed, for which we derive the optimal forgetting or tracking factor. This factor is found to be a function of both the noise variance and the channel Doppler spread. Through simulations, it is shown that the optimal pilot sequences derived in this paper outperform both the orthogonal and random pilot sequences. It is also shown that a considerable gain in signal-to-noise ratio (SNR) can be obtained by using the RLS algorithm, especially in slowly time-varying channels.
Cytokine generation in stored, white cell‐reduced, and bacterially contaminated units of red cells (1995)

IL-8 and IL-1 beta accumulated in the supernatants of stored RBCs despite cold storage conditions. IL-8 reached levels > 1000 pg per mL in the supernatants of some RBC units. IL-1 beta increased to significant but low levels (< 13 pg/mL). WBC filtration early in storage prevented the accumulation of IL-8. The physiologic significance to transfusion recipients of IL-8 in RBC supernatants is currently unknown and deserves further investigation.
Electrogenerated chemiluminescent determination of tris(2,2'-bipyridine)ruthenium ion (Ru(bpy)32+) at low levels (1984)

ADVERTISEMENT RETURN TO ISSUEPREVArticleNEXTElectrogenerated chemiluminescent determination of tris(2,2'-bipyridine)ruthenium ion (Ru(bpy)32+) at low levelsDeniz. Ege, William G. Becker, and Allen J. BardCite this: Anal. Chem. 1984, 56, 13, 2413–2417Publication Date (Print):November 1, 1984Publication History Published online1 May 2002Published inissue 1 November 1984https://pubs.acs.org/doi/10.1021/ac00277a036https://doi.org/10.1021/ac00277a036research-articleACS PublicationsRequest reuse permissionsArticle Views1055Altmetric-Citations139LEARN ABOUT THESE METRICSArticle Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.Citations are the number of other articles citing this article, calculated by Crossref and updated daily. Find more information about Crossref citation counts.The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on the Altmetric Attention Score and how the score is calculated. Share Add toView InAdd Full Text with ReferenceAdd Description ExportRISCitationCitation and abstractCitation and referencesMore Options Share onFacebookTwitterWechatLinked InRedditEmail Other access optionsGet e-Alertsclose Get e-Alerts
CLASSIFICATION OF CLINICAL SUBSETS EN PSORIATIC ARTHRITIS (1994)

The classification of PsA is controversial. Two recent papers have suggested new subgroup classifications, however both have served only to expand the controversy. In this study the clinical and radiologic features of 100 patients with PsA are recorded in order to examine possible clinical or radiologic features which may be associated with functional disability and to examine the usefulness of recent reclassification proposals in our patient population. Results indicate that an asymmetric oligoarthritis (AO) pattern of disease is most common occurring in 43%. A symmetric polyarthritis (SP) was present in 33%, and this subgroup had the highest number of erosions and deformities, and a higher proportion of patients with grade III/IV ARA functional disability. While the DIP joints were involved in 46%, predominant DIP joint disease occurred in 16%. As the DIP group had the shortest duration of arthritis, it may be that this group represents recent onset PsA which will evolve into one of the other subgroups. Sacroiliitis was a feature in 14% with predominant spondylitis (SPON) in 4%. Arthritis mutilans (AM) was rare occurring in only 2% of this population, perhaps representing patients with end-stage SP disease. Finally, 2% of patients had features of the synovitis-acne-pustulosis-hyperostosis-osteomyelitis (SAPHO) syndrome. A classification comprising just three subgroups (AO, SP, SPON) is proposed as being of most use clinically though a long-term prospective study is needed for verification.
CaMKII-δ Isoform Regulation of Neointima Formation After Vascular Injury (2007)

CaMKIIdelta2 is specifically induced in VSM and adventitial fibroblasts during the response of an artery to injury and is a positive regulator of proliferation and migration in the vessel wall contributing to neointima formation and vascular remodeling. This provides a potential mechanism for Ca2+-dependent regulation of VSM and myofibroblast proliferation and migration in response to vascular injury or disease.